Trevi Therapeutics Inc (TRVI)’s financial ratios: A comprehensive overview

The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.

In other words, the price has increased by $0.00 from its previous closing price. On the day, 1.76 million shares were traded. TRVI stock price reached its highest trading level at $6.49 during the session, while it also had its lowest trading level at $5.98.

Ratios:

Our analysis of TRVI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.38 and its Current Ratio is at 7.38. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Raymond James on March 10, 2025, Upgraded its rating to Strong Buy and sets its target price to $29 from $9 previously.

On March 10, 2025, Needham reiterated its Buy rating and also lowered its target price recommendation from $8 to $25.

H.C. Wainwright reiterated its Buy rating for the stock on December 12, 2024, while the target price for the stock was revised from $6 to $7.50.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 10 ’25 when Simon Farrell sold 81,313 shares for $6.75 per share. The transaction valued at 548,878 led to the insider holds 76,900 shares of the business.

Simon Farrell bought 81,313 shares of TRVI for $548,880 on Mar 10 ’25. On Sep 06 ’24, another insider, GOOD JENNIFER L, who serves as the President & CEO of the company, sold 4,219 shares for $3.03 each. As a result, the insider received 12,784 and left with 213,313 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TRVI now has a Market Capitalization of 563003904 and an Enterprise Value of 419873984.

Stock Price History:

The Beta on a monthly basis for TRVI is 0.39, which has changed by 1.0127795 over the last 52 weeks, in comparison to a change of 0.087141395 over the same period for the S&P500. Over the past 52 weeks, TRVI has reached a high of $7.39, while it has fallen to a 52-week low of $2.30. The 50-Day Moving Average of the stock is 47.28%, while the 200-Day Moving Average is calculated to be 90.20%.

Shares Statistics:

TRVI traded an average of 2.97M shares per day over the past three months and 7016660 shares per day over the past ten days. A total of 75.45M shares are outstanding, with a floating share count of 52.84M. Insiders hold about 40.87% of the company’s shares, while institutions hold 49.29% stake in the company. Shares short for TRVI as of 1740700800 were 3791658 with a Short Ratio of 1.28, compared to 1738281600 on 4592706. Therefore, it implies a Short% of Shares Outstanding of 3791658 and a Short% of Float of 6.1100002.

Dividends & Splits

Against a Trailing Annual Dividend Yield of 0.0

Most Popular